The USC Norris Comprehensive Cancer Center at the University of Southern California was founded in 1971 and has been continuously supported by a Cancer Center Support Grant since 1973. It has developed into a major regional and national resource for cancer research, treatment, prevention and education. Center facilities have been built and developed with support from the NCI, the University and the Kenneth Norris Jr. Cancer Hospital, which is an integral part of the Cancer Center. The Center underwent a major expansion with the addition of the Norman Topping Tower in 1996 and the Harlyne Norris Research Tower in 2007. The Center's 198 members are organized into five thematic and five translational research programs, including a """"""""bridge"""""""" program in developmental therapeutics. The thematic programs are headed by senior investigators in the fields of molecular genetics, epigenetics and regulation, tumor microenvironment, cancer epidemiology and cancer control research. The translational programs, which provide focus to our transdisciplinary research efforts, are in developmental therapeutics, genitourinary cancers, gastrointestinal cancers, women's cancers and leukemia and lymphoma. This application is for: 1) partial salary support for the Center's senior leadership, who are responsible for planning and overseeing our research efforts;2) support for program planning and evaluation to keep the Center at the forefront of cancer research;3) support for the administrative infrastructure of the Center;4) partial support for the Center's 11 shared resources which facilitate the conduct of our peer-reviewed research;and 5) support for developmental funds to help us recruit new investigators in areas we have targeted for expansion and to fund innovative pilot projects. Continued funding from the Cancer Center Core Support Grant will allow us to build on our strengths in basic and population-based research and to translate our underlying expertise into strong, peer-reviewed funded research programs focused on cancers of major consequence in this country. Cancer Center members currently hold grants totaling $125 million in direct costs, with $43 million of that coming from NCI (all exclusive of the CCSG).

Public Health Relevance

The USC Norris Comprehensive Cancer Center provides the infrastructure and resources to facilitate and foster translational research for the development of more effective prevention, diagnosis, treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-37S3
Application #
8545249
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1996-12-01
Project End
2015-11-30
Budget Start
2012-02-10
Budget End
2012-11-30
Support Year
37
Fiscal Year
2012
Total Cost
$74,999
Indirect Cost
$29,268
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications